Core Viewpoint - Baixinan-B (02185) has seen a significant increase of over 10%, currently up 13.5% at HKD 8.83, with a trading volume of HKD 106 million [1] Group 1: Market Developments - Boston Scientific is set to acquire SoniVie for a total price of USD 600 million by March 2025, indicating a strong entry into the RDN market [1] - The American College of Cardiology and the American Heart Association updated hypertension treatment guidelines in August, incorporating RDN as a Class IIb recommendation [1] - The proposed national coverage decision for RDN by the Centers for Medicare & Medicaid Services (CMS) in July, if approved, will significantly accelerate clinical adoption [1] Group 2: Industry Insights - Percutaneous renal denervation (RDN) is a new therapeutic device for uncontrolled and resistant hypertension [1] - According to Frost & Sullivan, the market size for RDN in China is expected to exceed RMB 10 billion by 2032 [1] - Baixinan's Iberis RDN system is the only globally approved device that can perform RDN via both transradial (TRA) and transfemoral approaches, providing a significant first-mover advantage [1] Group 3: Strategic Partnerships - Baixinan has established significant strategic partnerships with Yuan Da Health and various countries for commercial acceleration [1] - The Iberis RDN system has been included in health insurance coverage in Germany and France, further supporting Baixinan's commercialization efforts [1]
百心安-B再涨超13% RDN年内催化频出 机构称百心安商业化即将加速